Search - tctmd.com

Displaying 541 - 560 of 671

Sort: Relevancy | Date

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Presentation TCT 2012

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

Presenter: Marco Valgimigli

October 24, 2012

Presentation TCT 2012

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

Presenter: Fabio Mangiacapra

October 23, 2012

Presentation TCT 2012

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

Presenter: Michael Maeng

October 23, 2012

Presentation TCT 2012

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Presenter: Paul Gurbel

October 23, 2012

Presentation TCT 2012

TCT-52. Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding: The HORIZONS-AMI Trial

Presenter: Gregg Stone

October 23, 2012

Presentation TCT 2012

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

Presenter: Renato Valenti

October 23, 2012

$TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...$

Presentation TCT 2012

TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...

Presenter: Lamin King

October 23, 2012

Presentation TCT 2012

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Presenter: Joseph Jakubowski

October 23, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

Presenter: Paul Gurbel

October 22, 2012

Presentation TCT 2012

ISAR-SAFE Update

Presenter: Adnan Kastrati

October 22, 2012

Presentation TCT 2012

Do Patient and Stent Platform Specific Variables Matter (e.g. ACS vs. Stable CAD, First vs. Second Generation DES)?

Presenter: Elvin Kedhi

October 22, 2012

Presentation TCT 2012

DAPT Trial Update

Presenter: Laura Mauri

October 22, 2012

Presentation TCT 2012

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Presenter: Laurent Bonello

October 22, 2012

Presentation TCT 2012

A Prospective, Randomized Trial of Rosuvastatin Loading Prior to PCI

Presenter: Josef Veselka

October 22, 2012

Presentation TCT 2012

A Preview to OPTIMIZE

Presenter: Fausto Feres

October 22, 2012

Presentation

Bivalirudin vs. Heparin Plus a GPI in Pts with NSTEMI Undergoing PCI After Clopidogrel Pretreatment

Presenter: G. Ndrepepa

October 18, 2012

Presentation

Reduction in Platelet Reactivity with Prasugrel 5 mg in Low-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Weight Patients

Presenter: David Erlinge

October 17, 2012

Advertisement

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

TCT-52. Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding: The HORIZONS-AMI Trial

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

ISAR-SAFE Update

Do Patient and Stent Platform Specific Variables Matter (e.g. ACS vs. Stable CAD, First vs. Second Generation DES)?

DAPT Trial Update

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

A Prospective, Randomized Trial of Rosuvastatin Loading Prior to PCI

A Preview to OPTIMIZE

Bivalirudin vs. Heparin Plus a GPI in Pts with NSTEMI Undergoing PCI After Clopidogrel Pretreatment

Reduction in Platelet Reactivity with Prasugrel 5 mg in Low-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Weight Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content